OraSure Technologies (OSUR)
Makes OraQuick tests and sample-management devices for decentralized diagnostics.
Something off on this page? Send us feedback.
Sells rapid diagnostics for HIV and other conditions, plus sample-collection and stabilization devices for genomics and microbiome workflows. A single reportable segment houses products such as OraQuick, InteliSwab, Oragene, ORAcollect, OMNIgene, SickleSCAN, and the Sherlock molecular test pipeline.
Develops, manufactures, markets, sells, and distributes rapid diagnostics and sample-management solutions from Bethlehem, Pennsylvania. Product families include OraQuick HIV tests, other infectious-disease diagnostics for HCV, syphilis and Ebola, InteliSwab COVID-19 tests, and Genomics collection systems such as Oragene, ORAcollect and OMNIgene.
Uses oral-fluid, saliva, urine, blood and stool collection formats to support point-of-need testing and lab workflows. DNA Genotek anchors sample management; Sherlock adds a rapid molecular self-test platform; SickleSCAN adds point-of-care sickle-cell testing sold outside the United States.
Operates as one reportable segment, so the business is managed under a single reporting hierarchy rather than by product silo. COVID-19 test demand has normalized, and the Sherlock CT/NG self-test pipeline remains subject to regulatory approvals.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $160.6M · Total debt $12.1M · Total assets $360.6M · Shareholders' equity $317.8M
- Revenue
- $30.6M
- Operating income
- $5.4M
- Net income
- $6.2M
No dividends on record.
| Institutions | ≈ 80.14% | 55.18M shares | |
|---|---|---|---|
| 156 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 6.63% | 4.57M shares | |
| 12 holders · as of Sep 9, 2026 | |||
| Other | ≈ 13.23% | 9.11M shares | |
| remainder | |||
68.85M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.09% | 6.26M | as of Jun 30, 2026 |
Neuberger Berman Group LLCInstitution | 6.81% | 4.69M | as of Jun 30, 2026 |
Managed Account Advisors LLC000000000Institution | 6.28% | 4.32M | filed Jan 26, 2022 |
American Capital Management, Inc.Institution | 6.26% | 4.31M | filed Feb 16, 2021 |
Private Management Group IncInstitution | 5.52% | 3.80M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 12, 2026 | Steven Kyle Boyd | director | +25,000 | $2.98 |
| May 13, 2026 | Steven Kyle Boyd | director | +25,000 | $3.02 |
| May 14, 2026 | Steven Kyle Boyd | director | +25,000 | $2.99 |
| Mar 20, 2026 | Manner Carrie Eglinton | director, officer: President & CEO | +32,300 | $2.93 |
| Mar 20, 2026 | Kenneth J. McGrath | officer: Chief Financial Officer | +32,300 | $2.93 |
- Abbott
Broad rapid diagnostics and near-patient molecular testing overlap
- QuidelOrtho
Point-of-care infectious disease and COVID testing peer
- Danaher
Cepheid molecular diagnostics overlap with STI and POC pipeline
- BD
Rapid POC, molecular respiratory, and specimen-collection overlap
- Thermo Fisher Scientific
Sample collection and molecular workflow competitor
- Bio-Rad Laboratories
HIV, HCV, syphilis, and confirmatory infectious-disease assays
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OraSure Technologies | $3.95 | +7.03% | $254.1M | — | — | 2.3 | −1.9% |
| Abbott | $104.03 | +1.02% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| QuidelOrtho | $11.12 | +2.39% | $740.6M | — | 13.2 | 0.3 | +2.8% |
| Danaher | $221.55 | +2.65% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| BD | $181.96 | +0.70% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| Thermo Fisher Scientific | $661.62 | +0.43% | $244.81B | 35.4 | 25.2 | 5.3 | +10.5% |
| Bio-Rad Laboratories | $381.48 | +1.10% | $10.16B | 45.7 | 37.0 | 3.9 | −0.1% |
| Median | 38.3 | 21.5 | 3.9 | +4.2% |